[Study of the dose-reducing effect of acemetacin on prednisolon (author's transl)].
The dose-reducing effect of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy[ acetic acid (acemetacin, TV 1322, Rantudil¿) on prednisolon was studied on 22 patients suffering from rheumatoid arthritis. The average prednisolon-saving was 4.33 mg; in 31.8% of the patients it was possible to dispense with prednisolon completely (in 6 cases the reduction was 5 mg and in 1 case 7.5 mg). During the short test period the medication was well tolerated. Undesired gastro-intestinal drug reactions were not recorded for any of the patients. None of the investigated laboratory parameters revealed any pathological changes which were attributable to Acemetacin, but in one patient getting a long-term treatment with gold a decrease of lymphoid cell count was observed.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D007213:Indomethacin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007210:Indoleacetic Acids; C026784:acemetacin; D011239:Prednisolone; D007213:Indomethacin
Untersuchung des Prednisolon-einsparenden Effektes von Acemetacin.